Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025

Voyager Therapeutics, Inc.

2024-Q2 EPS reported -$0.37 revenue$49,094,000

Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.
Cash, equivalents and marketable securities at $371M as of June 30; runway into 2027.
First participants dosed in Phase 1a SAD of anti-tau antibody VY7523; top-line safety/PK data expected H1 2025.
Three gene therapy INDs on track for 2025: SOD1 ALS (VY9323), GBA1, and Friedreich's ataxia.
Appointed Nathan Jorgensen as CFO; received $3M milestone from Neurocrine for GBA1 candidate selection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.